title: Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure.
abstract: OBJECTIVE
  The aim of this study was to determine whether left ventricular ejection fraction (LVEF) influences the relationship between abnormal myocardial sympathetic innervation imaging by iodine 123 meta-iodobenzylguanidine ((123)I-mIBG) and outcomes in patients with heart failure (HF).
  
  
  BACKGROUND
  In systolic HF, both abnormal (123)I-mIBG imaging and reduced LVEF are associated with higher risk of cardiovascular events. Whether (123)I-mIBG imaging has the same predictive value across the LVEF spectrum is unclear.
  
  
  METHODS
  Among 985 patients in the ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) trial with New York Heart Association functional class II or III HF and site-reported LVEF ≤35%, the core laboratory-determined LVEFs were available for 901 subjects, ranging from 20% to 58% (mean LVEF 34 ± 7%), and was >35% in 386 subjects.
  
  
  RESULTS
  The mean age of the study population was 62 ± 12 years, 80% were male, and the majority had New York Heart Association functional class II symptoms and HF of nonischemic etiology. At all levels of LVEF, the (123)I-mIBG heart-to-mediastinum ratio of <1.6 was associated with a higher risk of death or potentially lethal arrhythmic event and of the composite of cardiovascular death, arrhythmic event, and HF progression. Comparing subjects with LVEF ≤35% and >35%, there was no evidence of effect modification of LVEF on the risk associated with low heart-to-mediastinum ratio for death or arrhythmic event (adjusted hazard ratio: 2.39 [95% confidence interval (CI): 1.03 to 5.55] vs. 5.28 [95% CI: 1.21 to 23.02]; interaction p = 0.48) and for the composite (adjusted hazard ratio: 1.80 [95% CI: 1.01 to 3.23] vs. 2.41 [95% CI: 1.11 to 5.23]; interaction; p = 0.86). For death or arrhythmic event, the heart-to-mediastinum ratio appeared to improve the risk discrimination beyond clinical and biomarker data among both LVEF groups, with improvement in the model C-statistic (0.67 vs. 0.69, p = 0.03) and integrated discrimination improvement (p = 0.0008).
  
  
  CONCLUSIONS
  (123)I-mIBG imaging has prognostic value across a spectrum of LVEFs. Further studies may be warranted to prospectively test the prognostic value of (123)I-mIBG imaging in patients with HF and an LVEF >35%.
authors.affiliation: Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. ashah11@rics.bwh.harvard.edu
authors.forename: Amil M
authors.initials: AM
authors.lastname: Shah
authors.forename: Mikhail
authors.initials: M
authors.lastname: Bourgoun
authors.forename: Jagat
authors.initials: J
authors.lastname: Narula
authors.forename: Arnold F
authors.initials: AF
authors.lastname: Jacobson
authors.forename: Scott D
authors.initials: SD
authors.lastname: Solomon
mesh_terms: D019797:3-Iodobenzylguanidine; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D006321:Heart / Q000294:innervation*; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis* / Q000000981:diagnostic imaging* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D018570:Risk Assessment; D012307:Risk Factors; D013318:Stroke Volume; D013564:Sympathetic Nervous System / Q000000981:diagnostic imaging*; D013997:Time Factors; D014481:United States; D016277:Ventricular Function, Left
chemical_list: D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine